Sarah Ellinwood, Ph.D. Joins Workforce Genetics as Managing Editor for BioBuzz Media Workforce Genetics welcomes molecular biologist Sarah Ellinwood, Ph.D., as its new Managing Editor. Sarah will be collaborating closely [….]
Workforce Genetics welcomes Erik Crown as the new Head of Marketing and Communications to be the head storyteller conveying the vision for both the Talent and BioBuzz Media divisions which offer a variety of services to life science employers across several functional areas.
In a rapidly expanding market, BioFactura is making waves in a big way in 2021. From initiation of a phase 1 study for a biosimilar treatment for people suffering from Crohn’s Disease to a recent transfer agreement with RANI Therapeutics, there’s a lot to be excited about for a company of just under 50 employees.
Longeviti Welcomes Renowned Neurosurgeon, Leading Cerebral Expert, Dr. David Langer as New Chief Medical Officer
Longeviti Neuro Solutions, developer of the first low-profile intracranial devices that meet the functional and reconstructive needs of brain surgery patients, has hired Dr. David Langer as chief medical officer. With more than 22 years of experience in highly personalized direct patient care and expertise in medical technology, Dr. Langer will develop and drive the clinical strategy to expand use of Longeviti’s innovative solutions for patients undergoing complex brain surgery.
With a goal of expanding manufacturing capabilities to meet the growing demands of cell and gene therapy production, The Center for Breakthrough Medicines (CBM) promoted Chief Operating Officer Joerg Ahlgrimm to the role of Chief Executive Officer. Ahlgrimm joined CBM last year after serving as Head of Global Operations Pharma Biotech and Nutrition at Lonza. CBM, located within the Discovery Labs campus in suburban Philadelphia, is a quickly growing contract development and manufacturing organization that aims to provide pre-clinical through commercial manufacturing capabilities for client companies. CBM’s offerings include process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.
TEDCO’s Tammi Thomas Selected for Leadership Greater Washington 2022 Cohort. Established over 35 years ago, LGW has developed nearly 2,000 executive-level leaders from the District of Columbia, Virginia, and Suburban Maryland through its flagship offering, the Signature Program. It’s an intensive ten-month program that exposes professionals to regional civic issues through education, connection, and knowledge sharing. With the purpose to leverage collective knowledge and resources to make the Greater Washington region a more dynamic and collaborative community.
Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.
Ariel Gruswitz, JD, has joined Facility Logix as associate director. She will be responsible for
leading the firm’s consulting services practice and expanding its Feasibility and Market Analysis
Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore
BioHealth Innovation Adds Diane Ignar, Ph.D. and Dr. Loleta Robinson as NIH New Entrepreneurs-in-Residence
BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.